Skip to main content
SpringerLink
Log in

Occupational- and Drug-Induced Disorders

  • Chapter
  • First Online:
Diffuse Lung Disease

  • 1548 Accesses

Abstract

Occupational, environmental, and medicinal agents remain one of the most common causes for interstitial lung diseases. A major problem with these diseases is recognition, since the number of exposures to new agents increases every year. In some cases, there are characteristics features of the presentation which suggest the diagnosis. For many, the pattern is not specific. In this chapter, these agents and their most common manifestations are presented. The clinician must consider these in evaluating a patient with interstitial lung disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sigerist HE. Civilization and disease. Ithaca: Cornell University Press; 1948.

    Google Scholar 

  2. Sigerist HE. The Wesley M. Carpenter Lecture: “Historical background of industrial and occupational diseases”. Bull N Y Acad Med. 1936;12(11): 597–609.

    PubMed  CAS  Google Scholar 

  3. Bracker A, Storey E. Assessing occupational and environmental exposures that cause lung disease. Clin Chest Med. 2002;23(4):695–705.

    Article  PubMed  Google Scholar 

  4. Henry DA. International Labor Office Classification System in the age of imaging: relevant or redundant. J Thorac Imaging. 2002;17(3):179–88.

    Article  PubMed  Google Scholar 

  5. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57(4):292–9.

    Article  PubMed  Google Scholar 

  6. Pipavath SN, Godwin JD, Kanne JP. Occupational lung disease: a radiologic review. Semin Roentgenol. 2010;45(1):43–52.

    Article  PubMed  Google Scholar 

  7. Diseases associated with exposure to silica and nonfibrous silicate minerals. Silicosis and Silicate Disease Committee. Arch Pathol Lab Med. 1988;112(7): 673–720.

    Google Scholar 

  8. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1666–80.

    PubMed  CAS  Google Scholar 

  9. De Vuyst P, Camus P. The past and present of pneumoconioses. Curr Opin Pulm Med. 2000;6(2):151–6.

    Article  PubMed  Google Scholar 

  10. Becklake MR. The mineral dust diseases. Tuber Lung Dis. 1992;73(1):13–20.

    Article  PubMed  CAS  Google Scholar 

  11. Becklake MR. When the chest X-ray does not tell the whole story: a tale of miners, selection bias, and the healthy worker effect. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1761–2.

    PubMed  CAS  Google Scholar 

  12. Doll NJ, Stankus RP, Barkman HW. Immunopath­ogenesis of asbestosis, silicosis, and coal workers’ pneumoconiosis. Clin Chest Med. 1983;4(1): 3–14.

    PubMed  CAS  Google Scholar 

  13. Glaspole IN, Wells AU, du Bois RM. Lung biopsy in diffuse parenchymal lung disease. Monaldi Arch Chest Dis. 2001;56(3):225–32.

    PubMed  CAS  Google Scholar 

  14. Wilt JL, Banks DE, Weissman DN, et al. Reduction of lung dust burden in pneumoconiosis by whole-lung lavage. J Occup Environ Med. 1996;38(6):619–24.

    Article  PubMed  CAS  Google Scholar 

  15. Pathology standards for coal workers’ pneumoconiosis. Report of the Pneumoconiosis Committee of the College of American Pathologists to the National Institute for Occupational Safety and Health. Arch Pathol Lab Med. 1979;103(8):375–432.

    Google Scholar 

  16. Jindal SK, Aggarwal AN, Gupta D. Dust-induced interstitial lung disease in the tropics. Curr Opin Pulm Med. 2001;7(5):272–7.

    Article  PubMed  CAS  Google Scholar 

  17. Stark P, Jacobson F, Shaffer K. Standard imaging in silicosis and coal worker’s pneumoconiosis. Radiol Clin North Am. 1992;30(6):1147–54.

    PubMed  CAS  Google Scholar 

  18. Shankar PS. Ventilatory study in simple coal worker’s pneumoconiosis. Indian J Med Sci. 1981;35(4):73–6.

    PubMed  CAS  Google Scholar 

  19. Ashcroft T. Asbestos bodies. Br Med J. 1968; 2(606):696–7.

    Article  PubMed  CAS  Google Scholar 

  20. Akira M, Yamamoto S, Inoue Y, Sakatani M. High-resolution CT of asbestosis and idiopathic pulmonary fibrosis. Am J Roentgenol. 2003;181(1):163–9.

    Google Scholar 

  21. Victor LD, Talamonti WJ. Asbestos lung disease. Hosp Pract (Off Ed). 1986;21(4):257–68.

    CAS  Google Scholar 

  22. Jones-Williams W. On the differential diagnosis of chronic beryllium disease and sarcoidosis. Am Rev Respir Dis. 1990;142(3):739–40.

    Article  PubMed  CAS  Google Scholar 

  23. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med. 1988;108(5):687–93.

    PubMed  CAS  Google Scholar 

  24. Uibu T, Vanhala E, Sajantila A, et al. Asbestos fibers in para-aortic and mesenteric lymph nodes. Am J Ind Med. 2009;52(6):464–70.

    Article  PubMed  Google Scholar 

  25. Fireman E, Greif J, Schwarz Y, et al. Assessment of hazardous dust exposure by BAL and induced sputum. Chest. 1999;115(6):1720–8.

    Article  PubMed  CAS  Google Scholar 

  26. Forni A. Bronchoalveolar lavage in the diagnosis of hard metal disease. Sci Total Environ. 1994;150(1–3): 69–76.

    PubMed  CAS  Google Scholar 

  27. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J Suppl. 2001;32:93s–100.

    PubMed  CAS  Google Scholar 

  28. Limper AH, Rosenow III EC. Drug-induced interstitial lung disease. Curr Opin Pulm Med. 1996;2(5):396–404.

    Article  PubMed  CAS  Google Scholar 

  29. Rosenow III EC, Myers JL, Swensen SJ, Pisani RJ. Drug-induced pulmonary disease. An update. Chest. 1992;102(1):239–50.

    Article  PubMed  Google Scholar 

  30. Rosenow III EC, Limper AH. Drug-induced pulmonary disease. Semin Respir Infect. 1995;10(2):86–95.

    PubMed  Google Scholar 

  31. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA. 2002;287(15):1968–71.

    Article  PubMed  Google Scholar 

  32. Kopko PM, Holland PV. Transfusion-related acute lung injury. Br J Haematol. 1999;105(2):322–9.

    Article  PubMed  CAS  Google Scholar 

  33. Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104(2):170–8.

    Article  PubMed  CAS  Google Scholar 

  34. Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol. 1997;1(1):47–56.

    Article  PubMed  CAS  Google Scholar 

  35. Ellis SJ, Cleverley JR, Muller NL. Drug-induced lung disease: high-resolution CT findings. AJR Am J Roentgenol. 2000;175(4):1019–24.

    PubMed  CAS  Google Scholar 

  36. Helman Jr DL, Byrd JC, Ales NC, Shorr AF. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. Chest. 2002;122(3):785–90.

    Article  PubMed  Google Scholar 

  37. Wesselius LJ. Pulmonary complications of cancer therapy. Compr Ther. 1999;25(5):272–7.

    Article  PubMed  CAS  Google Scholar 

  38. Aronin PA, Mahaley Jr MS, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980;303(4):183–8.

    Article  PubMed  CAS  Google Scholar 

  39. Schlaeffer F, Gold B, Hirsch M, Keynan A. A case of interstitial pneumonitis during amiodarone therapy. Isr J Med Sci. 1982;18(7):809–11.

    PubMed  CAS  Google Scholar 

  40. Sobol SM, Rakita L. Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation. 1982;65(4):819–24.

    Article  PubMed  CAS  Google Scholar 

  41. De Lena M, Guzzon A, Monfardini S, Bonadonna G. Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066). Cancer Chemother Rep. 1972;56(3):343–56.

    PubMed  Google Scholar 

  42. Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol. 1997;16(3):296–304.

    Article  PubMed  CAS  Google Scholar 

  43. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109(4): 933–8.

    Article  PubMed  CAS  Google Scholar 

  44. Foucher P, Biour M, Blayac JP, et al. Drugs that may injure the respiratory system. Eur Respir J. 1997;10(2):265–79.

    Article  PubMed  CAS  Google Scholar 

  45. Faller M, Quoix E, Popin E, et al. Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J. 1997;10(9):2159–62.

    Article  PubMed  CAS  Google Scholar 

  46. Dhillon SS, Singh D, Doe N, Qadri AM, Ricciardi S, Schwarz MI. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest. 1999;116(5):1485–8.

    Article  PubMed  CAS  Google Scholar 

  47. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet. 1999;353(9154):725–6.

    Article  PubMed  CAS  Google Scholar 

  48. Kastelik JA, Aziz I, Greenstone MA, Thompson R, Morice AH. Pergolide-induced lung disease in patients with Parkinson’s disease. Respir Med. 2002;96(7): 548–50.

    Article  PubMed  CAS  Google Scholar 

  49. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J. 2000;47(4):467–70.

    Article  PubMed  CAS  Google Scholar 

  50. Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener’s granulomatosis. Chest. 1996;110(2):556–9.

    Article  PubMed  CAS  Google Scholar 

  51. Skaer TL. Medication-induced systemic lupus erythematosus. Clin Ther. 1992;14(4):496–506.

    PubMed  CAS  Google Scholar 

  52. Qureshi RA, Ahmed TA, Grayson AD, Soorae AS, Drakeley MJ, Page RD. Does lung biopsy help patients with interstitial lung disease? Eur J Cardiothorac Surg. 2002;21(4):621–6.

    Article  PubMed  Google Scholar 

  53. Huang MS, Colby TV, Goellner JR, Martin Jr WJ. Utility of bronchoalveolar lavage in the diagnosis of drug-induced pulmonary toxicity. Acta Cytol. 1989;33(4):533–8.

    PubMed  CAS  Google Scholar 

  54. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol. 1987;18(4):349–54.

    Article  PubMed  CAS  Google Scholar 

  55. Bone RC, Wolfe J, Sobonya RE, et al. Desquamative interstitial pneumonia following long-term nitrofurantoin therapy. Am J Med. 1976;60(5):697–701.

    Article  PubMed  CAS  Google Scholar 

  56. Bergin CJ, Coblentz CL, Chiles C, Bell DY, Castellino RA. Chronic lung diseases: specific diagnosis by using CT. AJR Am J Roentgenol. 1989;152(6):1183–8.

    PubMed  CAS  Google Scholar 

  57. Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am. 2002;40(1):61–72.

    Article  PubMed  Google Scholar 

  58. Gondouin A, Manzoni P, Ranfaing E, et al. Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. Eur Respir J. 1996;9(7):1463–9.

    Article  PubMed  CAS  Google Scholar 

  59. Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol. 1977;128(1):1–13.

    PubMed  CAS  Google Scholar 

  60. Primack SL, Hartman TE, Hansell DM, Muller NL. End-stage lung disease: CT findings in 61 patients. Radiology. 1993;189(3):681–6.

    PubMed  CAS  Google Scholar 

  61. Screaton NJ, Hiorns MP, Muller NL. Differential diagnosis in chronic diffuse infiltrative lung disease on high-resolution computed tomography. Semin Roentgenol. 2002;37(1):17–24.

    Article  PubMed  Google Scholar 

  62. Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis. 1981;62(3):180–9.

    PubMed  CAS  Google Scholar 

  63. Robinson BW. Nitrofurantoin-induced interstitial pulmonary fibrosis. Presentation and outcome. Med J Aust. 1983;1(2):72–6.

    PubMed  CAS  Google Scholar 

  64. Zitnik RJ, Cooper Jr JA. Pulmonary disease due to antirheumatic agents. Clin Chest Med. 1990;11(1): 139–50.

    PubMed  CAS  Google Scholar 

  65. Tomioka R, King Jr TE. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med. 1997;155(3):1011–20.

    PubMed  CAS  Google Scholar 

  66. Bronchoalveolar T-cell subsets in gold lung. Evidence for a hypersensitivity reaction. Chest. 1985;87(1): 135–6.

    Google Scholar 

  67. Zisman DA, McCune WJ, Tino G, Lynch III JP. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3): 243–52.

    PubMed  CAS  Google Scholar 

  68. Sternlieb I, Bennett B, Scheinberg IH. D-penicillamine induced Goodpasture’s syndrome in Wilson’s disease. Ann Intern Med. 1975;82(5):673–6.

    PubMed  CAS  Google Scholar 

  69. Martin WJ. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med. 1990;11(1):131–8.

    PubMed  Google Scholar 

  70. Zhu YY, Botvinick E, Dae M, Golden J, Hattner R, Scheinman M. Gallium lung scintigraphy in ­amiodarone pulmonary toxicity. Chest. 1988;93(6): 1126–31.

    Article  PubMed  CAS  Google Scholar 

  71. Nordstrom L, Fletcher R, Pavek K. Shock of anaphylactoid type induced by protamine: a continuous cardiorespiratory record. Acta Anaesthesiol Scand. 1978;22(3):195–201.

    PubMed  CAS  Google Scholar 

  72. Kaufman J, Casanova JE, Riendl P, Schlueter DP. Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest. 1989;95(3):544–8.

    Article  PubMed  CAS  Google Scholar 

  73. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;20(5):1245–59.

    PubMed  CAS  Google Scholar 

  74. Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med. 1977;62(4): 608–15.

    Article  PubMed  CAS  Google Scholar 

  75. Smith AC. The pulmonary toxicity of nitrosoureas. Pharmacol Ther. 1989;41(3):443–60.

    Article  PubMed  CAS  Google Scholar 

  76. Ewig S, Glasmacher A, Ulrich B, Wilhelm K, Schafer H, Nachtsheim KH. Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: outcome and prognostic factors. Chest. 1998; 114(2):444–51.

    Article  PubMed  CAS  Google Scholar 

  77. Lauta VM, Valerio G, Greco A, Capece MM. Early-onset diagnosis of lung toxicity caused by cyclophosphamide, melphalan and procarbazine therapy. Tumori. 1987;73(4):351–8.

    PubMed  CAS  Google Scholar 

  78. Cohen MB, Austin JH, Smith-Vaniz A, Lutzky J, Grimes MM. Nodular bleomycin toxicity. Am J Clin Pathol. 1989;92(1):101–4.

    PubMed  CAS  Google Scholar 

  79. Okuno SH, Frytak S. Mitomycin lung toxicity. Acute and chronic phases. Am J Clin Oncol. 1997;20(3):282–4.

    Article  PubMed  CAS  Google Scholar 

  80. Whitcomb ME. Drug-induced lung disease. Chest. 1973;63(3):418–22.

    Article  PubMed  CAS  Google Scholar 

  81. Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics. 1999;103(2):E19.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Critical Care Medicine CMKP, 231 Czerniakowska Street, 00-416, Warszawa, Poland

    Michal Pirozynski MD, PhD

  2. Medicines Authority, Post-Licensing Directorate, Rue D’Argens, Gzira, GZR 1368, MALTA

    John Joseph Borg PhD

Authors
  1. Michal Pirozynski MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Joseph Borg PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michal Pirozynski MD, PhD .

Editor information

Editors and Affiliations

  1. University of Cincinnati, College of Medicine, Department of Internal Medicine, Eden Ave, Cincinnati, 45267-0565, Ohio, USA

    Robert P. Baughman

  2. of Respiratory Medicine, Imperial College, Emeritus Professor, Grand Ave 14, London, N10 3BB, United Kingdom

    Roland M. du Bois

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pirozynski, M., Borg, J.J. (2012). Occupational- and Drug-Induced Disorders. In: Baughman, R., du Bois, R. (eds) Diffuse Lung Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9771-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9771-5_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9770-8

  • Online ISBN: 978-1-4419-9771-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation